MA
MAIA.US MAIA Biotechnology Inc.
- Market cap
- USD 61.8M
- P/E
- -
- P/B
- 4.21x
- ROE
- -195.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MAIA.US undervalued?
Graham numberThe Graham number of MAIA Biotechnology Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
MAIA Biotechnology Inc. fundamental analysis
No fundamental analysis for MAIA Biotechnology Inc. yet.
MAIA Biotechnology Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
Full company profileMAIA Biotechnology Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
MAIA Biotechnology Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -6.92M | -6.98M | -7.79M | -16.2M | -20.2M | -17.0M | -24.3M | -31.1M |
| EBITDA | 242.00 | -6.98M | -11.8M | -15.8M | -19.8M | -23.3M | -22.4M | -28.2M |
| Net Income | -6.49M | -6.64M | -12.5M | -15.8M | -19.8M | -23.3M | -22.4M | -28.7M |
| EPS | -0.61 | -0.62 | -1.18 | -1.70 | -1.49 | -1.05 | -0.70 | -0.47 |
| Balance Sheet | ||||||||
| Total Assets | 1.73M | 747K | 11.3M | 12.0M | 7.57M | 10.2M | 9.70M | 22.1M |
| Total Liabilities | 410K | 2.36M | 2.15M | 3.51M | 7.09M | 6.52M | 7.33M | 7.43M |
| Shareholders' Equity | -173K | -3.34M | 9.18M | 8.51M | 478K | 3.63M | 2.38M | 14.7M |
| Cash & Short-term Investments | 1.71M | 663K | 10.6M | 11.0M | 7.15M | 9.60M | 8.66B | 21.3M |
| Total Debt | 34.2K | 464K | - | - | - | - | - | - |
| Cash Flow | ||||||||
| Operating Cash Flow | -1.57M | -1.84M | -4.12M | -12.1M | -13.1M | -15.7M | -18.8M | -24.5M |
| Capital Expenditure | 2.00 | 0.00 | 0.00 | 0.00 | 4.00 | 0.00 | 0.00 | 2.67 |
| Free Cash Flow | -1.57M | -1.84M | -4.12M | -12.1M | -13.1M | -15.7M | -18.8M | -24.5M |
| Ratios | ||||||||
| ROE | - | - | -136.2% | -185.4% | -4,140.8% | -639.8% | -942.7% | -195.3% |
| ROA | -374.3% | -889.0% | -110.4% | -131.2% | -261.3% | -229.0% | -230.8% | -129.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
MAIA Biotechnology Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | USD 58.2K | 0.01 | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns MAIA Biotechnology Inc.
- Insiders 14.41%
- Institutions 22.28%
- Public & others 63.32%
- Shares outstanding 61.8M
- Free float 55.3M
MAIA Biotechnology Inc. company profile
- Company name
- MAIA Biotechnology Inc.
- Ticker
- MAIA.US
- Exchange
- USA Stocks
- Listed since
- Jul 28, 2022
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 13
- Fiscal year end
- December
- Address
- 444 West Lake Street, Chicago, IL, United States, 60606
- Phone
- 312 416 8592
- Website
- maiabiotech.com
About MAIA Biotechnology Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.
MAIA Biotechnology Inc. management
4- Dr. Vlad Vitoc M.B.A., M.D.Co-Founder, President, CEO & Chairman of the Board of Directors · born 1970
- Mr. Jeffrey C. Himmelreich M.B.A.Head of Finance and Principal Financial & Accounting Officer · born 1976
- Dr. Sergei M. Gryaznov Ph.D.Chief Scientific Officer · born 1960
- Linda MoreiraCompany Secretary